Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis

被引:182
|
作者
Hahn, Virginia S. [1 ]
Yanek, Lisa R. [2 ]
Vaishnav, Joban [1 ]
Ying, Wendy [1 ]
Vaidya, Dhananjay [2 ]
Lee, Yi Zhen Joan [1 ]
Riley, Sarah J. [1 ]
Subramanya, Vinita [3 ]
Brown, Emily E. [1 ]
Hopkins, C. Danielle [1 ]
Ononogbu, Sandra [1 ]
Mandell, Kira Perzel [4 ]
Halushka, Marc K. [4 ]
Steenbergen, Charles, Jr. [4 ]
Rosenberg, Avi Z. [4 ]
Tedford, Ryan J. [5 ]
Judge, Daniel P. [5 ]
Shah, Sanjiv J. [6 ]
Russell, Stuart D. [7 ]
Kass, David A. [1 ]
Sharma, Kavita [1 ]
机构
[1] Johns Hopkins Sch Med, Div Cardiol, Baltimore, MD USA
[2] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA
[3] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[4] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA
[5] Med Univ South Carolina, Div Cardiol, Charleston, SC 29425 USA
[6] Northwestern Univ, Div Cardiol, Chicago, IL 60611 USA
[7] Duke Univ, Div Cardiol, Durham, NC USA
基金
美国国家卫生研究院;
关键词
amyloidosis; biopsy; fibrosis; HFpEF; inflammation; hypertrophy; NATURAL-HISTORY; ECHOCARDIOGRAPHY; INFLAMMATION; PHENOTYPE; STIFFNESS; TRENDS;
D O I
10.1016/j.jchf.2020.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study prospectively evaluated endomyocardial biopsies in patients with heart failure with preserved ejection fraction (HFpEF) to identify histopathotogic phenotypes and their association with clinical characteristics. BACKGROUND Myocardial tissue analysis from a prospectively defined HFpEF cohort reflecting contemporary comorbidities is lacking. METHODS Patients with HFpEF (EF >= 50%) referred to the Johns Hopkins HFpEF Clinic between August 2014 and September 2018 were enrolled for right heart catheterization and endomyocardiat biopsy. Clinical features, echocardiography, hemodynamics, and tissue histology were determined and compared with controls (unused donor hearts) and HF with reduced EF (HFrEF). RESULTS Of the 108 patients enrolled, median age was 66 years (25th to 75th percentile: 57 to 74 years), 61% were women, 57% were African American, 62% had a previous HF hospitalization, median systolic blood pressure was 141 mm Hg (25th to 75th percentile: 125 to 162 mm Hg), body mass index (BMI) was 37 kg/m(2) (25th to 75th percentile: 32 to 45 kg/m(2)), and 97% were on a loop diuretic. Myocardial fibrosis and myocyte hypertrophy were often present (93% and 88%, respectively); however, mild in 71% with fibrosis and in 52% with hypertrophy. Monocyte infiltration (CD68-rcells/mm(2)) was greater in patients with HFpEF versus controls (60.4 cells/mm(2) [25th to 75th percentile: 36.8 to 97.8] vs. 32.1 cells/mm(2) [25th to 75th percentile: 22.3 to 59.2]; p = 0.02) and correlated with age and renal disease. Cardiac amytoidosis (CA) was diagnosed in 15 (14%) patients (HFpEF-CA: 7 patients with wild-type transthyretin amytoidosis (ATTR], 4 patients with hereditary ATTR, 3 patients with tight-chain amytoidosis, and 1 patient with AA (secondary) amytoidosis), of which 7 cases were unsuspected. Patients with HFpEF-CA were older, with tower BMI, higher left ventricular mass index, and higher N-terminal pro 8-type natriuretic peptide and troponin 1 levels. CONCLUSIONS In this large, prospective myocardial tissue analysis of HFpEF, myocardial fibrosis and hypertrophy were common, CD68+ inflammation was increased, and CA prevalence was 14%. Tissue analysis in HFpEF might improve precision therapies by identifying relevant myocardial mechanisms. (C) 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:712 / 724
页数:13
相关论文
共 50 条
  • [1] Tissue is the Issue: Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Cardiac Amyloidosis
    Hahn, Virginia S.
    Ying, Wendy
    Lee, Yizhen J.
    Yanek, Lisa R.
    Vaidya, Dhananjay
    Subramanya, Vinita
    Riley, Sarah
    Mandell, Kira Perzel
    Halushka, Marc K.
    Rosenberg, Avi Z.
    Judge, Daniel P.
    Kass, David A.
    Russell, Stuart D.
    Sharma, Kavita
    CIRCULATION, 2019, 140
  • [2] Tissue is the Issue: Endomyocardial Biopsy Characterization of Heart Failure with Preserved Ejection Fraction and Incident Cardiac Amyloidosis
    Hahn, Virginia S.
    Ying, Wendy
    Lee, Yi Zhen Joan
    Yanek, Lisa R.
    Vaidya, Dhananjay
    Subramanya, Vinita
    Riley, Sarah J.
    Mandell, Kira Perzel
    Halushka, Marc
    Rosenberg, Avi
    Judge, Daniel P.
    Kass, David A.
    Russell, Stuart D.
    Sharma, Kavita
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S53 - S53
  • [3] Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?
    Lund, Lars H.
    Eldhagen, Per
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (12) : 2387 - 2389
  • [4] Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction
    Healy, L.
    Giblin, G.
    Gray, A.
    Starr, N.
    Murphy, L.
    O'Sullivan, D.
    Kavanagh, E.
    Howley, C.
    Tracey, C.
    Morrin, E.
    Mcdaid, A.
    Clarke, A.
    O'Neill, J. O.
    Joyce, E.
    O'Connell, M.
    Mahon, N. G.
    ESC HEART FAILURE, 2025, 12 (02): : 1176 - 1182
  • [5] Heart Failure with Preserved Ejection Fraction and Cardiac Amyloidosis in the Aging Heart
    Tana, Marco
    Piccinini, Rachele
    Moffa, Livia
    Tana, Claudio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (21)
  • [6] The prevalence of transthyretin amyloidosis in patients with heart failure with preserved ejection fraction
    Oh, J. Jaewon
    Kim, S. E.
    Lee, S.
    Lee, C. J.
    Kang, S. M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 359 - 359
  • [7] Prevalence of transthyretin amyloidosis in patients with heart failure with preserved ejection fraction
    Naito, T.
    Nakamura, K.
    Abe, Y.
    Sakuragi, S.
    Kihara, H.
    Okizaki, A.
    Kawai, Y.
    Watanabe, H.
    Yoshikawa, M.
    Takaishi, A.
    Fujio, H.
    Otsuka, H.
    Ogura, S.
    Nomura, N.
    Ito, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1079 - 1079
  • [8] True prevalence of transthyretin cardiac amyloidosis in an unselected heart failure with preserved ejection fraction cohort
    Achten, A. Anouk
    Van Empel, V. P. M.
    Weerts, J.
    Mourmans, S.
    Rocca, H. P. Brunner-La
    Wijk, S. Sanders-Van
    Knackstedt, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 47 - 48
  • [9] PREVALENCE OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A POPULATION BASED STUDY
    Abou-Ezzeddine, Omar Farid
    Davies, Daniel
    Sexton, Jasmine A.
    Scott, Christopher G.
    Fayyaz, Ahmed
    Akhiyat, Nadia
    Stromme, Trevor A.
    Askew, John W.
    McKie, Paul
    Noseworthy, Peter
    Dunlay, Shannon
    Borlaug, Barry
    Chareonthaitawee, Panithaya
    Johnson, Geoffrey
    Dispenzieri, Angela
    Grogan, Martha
    Redfield, Margaret M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 691 - 691
  • [10] Cardiac Amyloidosis. Redefining heart failure with preserved ejection fraction
    Gabilondo, Ivan
    Cartasegna, Luis
    Camilletti, Jorge
    Manganiello, Carlos F.
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2020, 49